Remdesivir treatment reduces cardiovascular complications in kidney transplant recipients with COVID-19

A target trial emulation study published in JAMA Network Open reveals that early remdesivir treatment significantly benefits adult kidney transplant recipients with COVID-19. Analyzing 432 patients, researchers found that a three-day course of remdesivir within a week of diagnosis is associated with a 47% lower risk of all-cause graft loss and a 42% lower risk of cardiovascular complications up to a year later, potentially by reducing systemic inflammation and blood vessel damage.

Remdesivir reduces graft loss

• ▪In the study of 432 adult kidney transplant recipients, 48 patients experienced all-cause graft loss, which was defined as graft failure or death from any cause.
• ▪A target trial emulation study found early remdesivir treatment was associated with a 47% lower risk of all-cause graft loss in adult kidney transplant recipients with COVID-19.

Cardiovascular complication reduction

• ▪In the study of 432 adult kidney transplant recipients, 43 patients experienced cardiovascular complications, including heart attacks, strokes, or cardiac-related deaths.
• ▪Early remdesivir treatment was associated with a 42% lower risk of cardiovascular events in adult kidney transplant recipients with COVID-19.

Study methodology

• ▪The target trial emulation study, published in JAMA Network Open, analyzed 432 adult kidney transplant recipients diagnosed with COVID-19 between March 2020 and January 2024.
• ▪The study compared 177 patients receiving at least a three-day course of intravenous remdesivir within a week of diagnosis against 255 patients who did not.

Patient population characteristics

• ▪At the time of COVID-19 diagnosis, 59% of the study participants stopped taking an immunosuppressive drug needed to prevent transplant rejection.
• ▪Of the 432 study participants, 95% had high blood pressure, 46% had diabetes, 15% had coronary artery disease, and 20% required supplemental oxygen at diagnosis.

Treatment timing considerations

• ▪Early suppression of viral replication by remdesivir may reduce systemic inflammation, endothelial injury, blood vessel damage, and severe blood clotting complications.
• ▪Physicians consider immune function, kidney health, immunosuppressive therapies, drug interactions, side effects, and COVID-19 timing and severity when treating kidney transplant recipients.